SVSara Vázquez-Mera

Sara Vázquez-Mera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sara Vázquez-Mera has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Francisco Javier Salgado

    BioLympho Research Group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

    5 shared publications
  • Juan José Nieto-Fontarigo

    BioLympho Research Group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

    5 shared publications
  • Laura Martelo-Vidal

    BioLympho Research Group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain

    4 shared publications
  • Francisco Javier González-Barcala

    Department of Respiratory Medicine, University Hospital of Santiago de Compostela, Rúa da Choupana, S/n, 15706, Santiago de Compostela, Spain; Spanish Biomedical Research Networking Centre-CIBERES, Rúa Do Franco, S/n, 15782, Santiago de Compostela, Spain; Health Research Institute of Santiago de Compostela (FIDIS), Travesía da Choupana, 15706, Santiago de Compostela, Spain

    3 shared publications
  • Pablo Miguéns‐Suárez

    Department of Biochemistry and Molecular Biology, Faculty of Biology‐Biological Research Centre (CIBUS) Universidade de Santiago de Compostela Santiago de Compostela Spain

    3 shared publications
  • Susana Belen Bravo

    Proteomic Unit Health Research Institute of Santiago de Compostela (IDIS) Santiago de Compostela Spain

    3 shared publications

Latest Publications

  • Open Access

    Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma

    by Pablo Miguéns‐Suárez, Sara Vázquez‐Mera, Laura Martelo‐Vidal, Marina Blanco Aparicio, Uxío Calvo Álvarez, Coral González Fernández, Mar Mosteiro Añón, Dolores Corbacho Abelaira, Tamara Hermida Valverde, Christian Calvo Henríquez, et al.

    Background: Mepolizumab, an anti‐IL5 monoclonal antibody, effectively reduces exacerbations and improves disease control in severe eosinophilic asthma (SEA). While this treatment rapidly decreases blood eosinophil counts, some patients continue to experience asthma symptoms, suggesting that other features beyond eosinophil number contribute to disease persistence. In this work, we aim to characterize the molecular and functional signature of circulating eosinophils in SEA in response to mepolizumab therapy. Methods: We performed proteomic (LC–MS/MS) and targeted transcriptomic (Nanostring) analyses on isolated blood eosinophils from healthy individuals and SEA patients at baseline and after 4, 16 and 32 weeks of treatment with mepolizumab. Western blot was used to validate selected genes and proteins. Results: Eosinophils from healthy donors and post‐treatment SEA patients exhibit lower levels of proteins related to cytoskeleton (e.g., GSN, DBNL, ARPC2 and ARPC3), suggesting a lower potential for migration and tissue extravasation. Several proteins (e.g., EPX and NCF2) and genes (e.g., CCL23 and SOCS3) directly involved in eosinophil effector functions, including ROS generation and degranulation, were significantly downregulated after mepolizumab treatment. The downregulation of GSN (actin‐binding protein), NCF2 (subunit of the NADPH oxidase complex) and EPX (eosinophil‐specific granule protein), was further validated by western blot. Conclusions: Our multi‐omic analysis suggests that mepolizumab reduces the migratory capacity and effector‐related molecular signatures of circulating eosinophils in SEA patients. Selected proteins, including GSN, NCF2 and EPX, may serve as candidate biomarkers for monitoring response to therapy.

  • Open Access

    Urinary Proteome and Exosome Analysis Protocol for the Discovery of Respiratory Diseases Biomarkers

    by Laura Martelo-Vidal, Sara Vázquez-Mera, Pablo Miguéns-Suárez, Susana Belén Bravo-López, Heidi Makrinioti, Vicente Domínguez-Arca, Javier De-Miguel-Díez, Alberto Gómez-Carballa, Antonio Salas, Francisco Javier González-Barcala, et al.

    This study aims to develop a protocol for respiratory disease-associated biomarker discovery by combining urine proteome studies with urinary exosome components analysis (i.e., miRNAs). To achieve this, urine was DTT treated to decrease uromodulin, then concentrated and ultracentrifuged. Proteomic analyses of exosome-free urine were performed using LC-MS/MS. Simultaneously, miRNA expression from urine exosomes was measured using either RTqPCR (pre-amplification) or nCounter Nanostring (non-amplication) analyses. We detected 548 different proteins in exosome-free urine samples (N = 5) with high confidence (FDR < 1%), many of them being expressed in different non-renal tissues. Specifically, lung-related proteins were overrepresented (Fold enrichment = 1.31; FDR = 0.0335) compared to whole human proteome, and 10–15% were already described as protein biomarkers for several pulmonary diseases. Urine proteins identified belong to several functional categories important in respiratory pathology. We could confirm the expression of miRNAs previously connected to respiratory diseases (i.e., miR-16-5p, miR-21-5p, miR-146a-5p, and miR-215-5p) in urine exosomes by RTqPCR. Finally, we detected 333 miRNAs using Nanostring, 15 of them up-regulated in T2high asthma (N = 4) compared to T2low asthma (N = 4) and healthy subjects (N = 4). Therefore, this protocol combining the urinary proteome (exosome free) with the study of urinary exosome components (i.e., miRNAs) holds great potential for molecular biomarker discovery of non-renal and particularly respiratory pathologies.

  • Open Access

    Signature Proteins in Small Extracellular Vesicles of Granulocytes and CD4+ T-Cell Subpopulations Identified by Comparative Proteomic Analysis

    by Sara Vázquez-Mera, Pablo Miguéns-Suárez, Laura Martelo-Vidal, Sara Rivas-López, Lena Uller, Susana B. Bravo, Vicente Domínguez-Arca, Xavier Muñoz, Francisco J. González-Barcala, Juan J. Nieto Fontarigo, et al.

    Several studies have described the proteomic profile of different immune cell types, but only a few have also analysed the content of their delivered small extracellular vesicles (sEVs). The aim of the present study was to compare the protein signature of sEVs delivered from granulocytes (i.e., neutrophils and eosinophils) and CD4+ T cells (i.e., TH1, TH2, and TH17) to identify potential biomarkers of the inflammatory profile in chronic inflammatory diseases. Qualitative (DDA) and quantitative (DIA-SWATH) analyses of in vitro-produced sEVs revealed proteome variations depending on the cell source. The main differences were found between granulocyte- and TH cell-derived sEVs, with a higher abundance of antimicrobial proteins (e.g., LCN2, LTF, MPO) in granulocyte-derived sEVs and an enrichment of ribosomal proteins (RPL and RPS proteins) in TH-derived sEVs. Additionally, we found differentially abundant proteins between neutrophil and eosinophil sEVs (e.g., ILF2, LTF, LCN2) and between sEVs from different TH subsets (e.g., ISG15, ITGA4, ITGB2, or NAMPT). A “proof-of-concept” assay was also performed, with TH2 biomarkers ITGA4 and ITGB2 displaying a differential abundance in sEVs from T2high and T2low asthma patients. Thus, our findings highlight the potential use of these sEVs as a source of biomarkers for diseases where the different immune cell subsets studied participate, particularly chronic inflammatory pathologies such as asthma or chronic obstructive pulmonary disease (COPD).


  • Open Access

    Exploring CD26−/lo subpopulations of lymphocytes in asthma phenotype and severity: A novel CD4+ T cell subset expressing archetypical granulocyte proteins

    by Sara Vázquez‐Mera, Laura Martelo‐Vidal, Pablo Miguéns‐Suárez, Susana Belén Bravo, Paula Saavedra‐Nieves, Pilar Arias, Antía Ferreiro‐Posse, Juan Vázquez‐Lago, Francisco Javier Salgado, Francisco Javier González‐Barcala, et al.

    Background: Asthma pathology may induce changes in naïve/memory lymphocyte proportions assessable through the evaluation of surface CD26 (dipeptidyl peptidase 4/DPP4) levels. Our aim was to investigate the association of asthma phenotype/severity with the relative frequency of CD26−/lo, CD26int and CD26hi subsets within different lymphocyte populations.Methods: The proportion of CD26−/lo, CD26int and CD26hi subsets within CD4+ effector T cells (Teff), total CD4− lymphocytes, γδ‐T cells, NK cells and NKT cells was measured in peripheral blood samples from healthy (N = 30) and asthma (N = 119) donors with different phenotypes/severities by flow cytometry. We performed K‐means clustering analysis and further characterised the CD4+CD26−/lo Teff cell subset by LC–MS/MS and immunofluorescence.Results: Cluster analysis including clinical and flow cytometry data resulted in four groups, two of them with opposite inflammatory profiles (neutrophilic vs. eosinophilic). Neutrophilic asthma presented reduced CD4−CD26hi cells, which negatively correlated with systemic inflammation. Eosinophilic asthma displayed a general expansion of CD26−/lo subsets. Specifically, CD4+CD26−/lo Teff expansion was confirmed in asthma, especially in atopic patients. Proteomic characterisation of this subset with a TEM/TEMRA phenotype revealed upregulated levels of innate (e.g. MPO and RNASE2) and cytoskeleton/extracellular matrix (e.g. MMP9 and ACTN1) proteins. Immunofluorescence assays confirmed the presence of atypical proteins for CD4+ T cells, and an enrichment in ‘flower‐like’ nuclei and MMP9/RNASE2 levels in CD4+CD26−/lo Teff compared to CD4+ T lymphocytes.Conclusion: There is an association between CD26 levels in different lymphocyte subsets and asthma phenotype/severity. CD4+CD26−/loTEMRA cells expressing innate proteins specific to eosinophils/neutrophils could be determinant in sustaining long‐term inflammation in adult allergic asthma.


  • Clustering analysis of asthma patients based on lymphocytes subpopulations: CD4+CD26-/lo T cells with a TEM/TEMRA phenotype blur the innate‑adaptive frontier in allergic asthma

    by Sara Vázquez-Mera, Pablo Miguéns-Suárez, Laura Martelo-Vidal, Paula Saavedra-Nieves, Susana Belén Bravo, Antía Ferreiro-Posse, Marina Blanco-Aparicio, Mar Mosteiro-Añón, Juan José Nieto-Fontarigo, Francisco Javier Salgado, et al.

    Asthma is a chronic inflammatory disease which encompasses a heterogeneous group of patients. Despite sharing respiratory symptoms produced by airway inflammation and remodelling, the underlying pathophysiological mechanism varies among individuals. Here, we aimed to explore the association between effector/memory lymphocyte subsets defined based on CD26 levels (CD26−/lo, CD26int and CD26hi) and specific asthma phenotypes. To do so, we have measured CD26 by flow cytometry in conventional CD4+ T cells, CD4− lymphocytes, γδ-T cells, NK, and NKT cells from healthy donors (N = 30) and asthma patients (N = 119) with different phenotypes/severity. Cluster analysis including flow cytometry and clinical data resulted in 4 groups of donors, two with opposite types of inflammation (eosinophilic vs. neutrophilic). Additionally, we have confirmed the expansion of CD4+CD26−/lo T cells (TEM/TEMRA) in asthma (p = 0.009), especially in atopic patients compared to HC (p = 0.016). Furthermore, their characterisation by LC-MS/MS (N = 4) revealed increased levels (log2 fold-change > 1) of proteins related to different innate cells (e.g., MPO, RNASE2) and extracellular matrix (e.g., MMP9) compared with total CD4+ T cells. Finally, immunofluorescence analysis validated these findings, alongside with an enrichment in cells with "flower-like" nuclei. Therefore, our study demonstrates an association between asthma phenotypes and different memory populations, and especially a potential role of a highly differentiated effector-memory Th cell population (CD4+CD26−/lo T cells) to sustain the disease and cause relapses.

  • Serum exosome inflamma‐miRs are surrogate biomarkers for asthma phenotype and severity

    by Sara Vázquez‐Mera, Laura Martelo‐Vidal, Pablo Miguéns‐Suárez, Paula Saavedra‐Nieves, Pilar Arias, Coral González‐Fernández, Mar Mosteiro‐Añón, María Dolores Corbacho‐Abelaira, Marina Blanco‐Aparicio, Paula Méndez‐Brea, et al.

    Background: Asthma is a heterogeneous disease with several phenotypes, endotypes and severity degrees, in which different T‐cell subpopulations are involved. These cells express specific miRNAs (i.e. inflamma‐miRs) that can be released to serum in exosomes after activation and be used as biomarkers of underlying inflammation. Thus, we aim to evaluate specific T‐cell miRNA signatures in serum exosomes from different subgroups of asthmatic patients.Methods: Samples from healthy donors (N = 30) and patients (N = 119) with different asthma endotypes (T2high‐Atopic/T2high‐Non‐atopic/T2low) and severity degrees (mild/MA and moderate–severe/MSA) were used. Demographic, clinical, haematological and biochemical characteristics were collected. Twelve miRNAs previously associated with different Th subsets were preselected and their levels in serum exosome samples were measured using RTqPCR.Results: We detected five miRNAs with high confidence in serum exosomes: miR‐16‐5p, miR‐21‐5p, miR‐126‐3p, miR146a‐5p and miR‐215‐5p. All of them, except miR‐16‐5p were upregulated in MSA patients compared to MA. A logistic regression model including each of these miRNAs was created to discriminate both conditions, rendering a ROC curve AUC of 0.896 (0.830–0.961). miR‐21‐5p and miR‐126‐3p, both involved in Th1/Th2 differentiation, were specifically augmented in T2high‐Atopic patients. Of note, all these changes were found in samples collected in autumn. On the contrary, IL‐6high patients with MSA, which were more obese, older, with higher neutrophil and basophil counts and TNF levels, displayed a decrease of miR‐21‐5p, miR‐126‐3p and miR‐146a‐5p.Conclusion: Immune‐related miRNAs, including miR‐21‐5p, miR‐126‐3p, miR‐146a‐5p and miR‐215‐5p, can be used as clinically relevant non‐invasive biomarkers of the phenotype/endotype and severity of asthma.